Irinotecan Viatris

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Viatris, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It treats metastatic colorectal cancer, serves as adjuvant therapy for colon cancer, and is used in combination for small cell lung cancer. GNH USA supplies Irinotecan Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Irinotecan is a topoisomerase I inhibitor employed in chemotherapy for gastrointestinal and lung cancer indications. - Metastatic colorectal cancer: improves overall survival when used in combination regimens. - Adjuvant treatment of colon cancer: reduces the risk of disease recurrence after surgical resection. - Small cell lung cancer (in combination): enhances response rates when combined with other chemotherapeutic agents.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: may be severe and require supportive care. - Nausea and vomiting: often managed with antiemetics. - Alopecia: temporary hair loss. - Fatigue: general tiredness during treatment. - Anemia: decreased red blood cell count.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils indicating infection. - Severe colitis: life‑threatening inflammation of the colon. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes or liver dysfunction. - Pulmonary toxicity: interstitial pneumonitis. - Tumor lysis syndrome: metabolic disturbances from rapid tumor cell death.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor for toxicity. - Blood count monitoring: perform complete blood counts regularly to detect neutropenia. - Liver function assessment: evaluate hepatic enzymes before and during treatment. - Bowel assessment: screen for pre‑existing diarrhea or bowel obstruction. - Pregnancy avoidance: contraindicated in pregnancy; use effective contraception. - Dose adjustment: consider reduced dosing in patients with hepatic impairment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase SN‑38 exposure. - Concurrent myelosuppressive agents: heighten risk of severe neutropenia. - High‑dose radiation therapy: can exacerbate gastrointestinal toxicity. - Live vaccines: increased risk of infection due to immunosuppression. - UGT1A1*28 homozygosity: markedly higher SN‑38 levels, avoid standard dosing.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce drug effectiveness. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Diuretics: watch for electrolyte imbalances. - Other antineoplastic agents: adjust dosing to manage overlapping toxicities. - Antiemetics (e.g., ondansetron): may affect metabolism, monitor for altered SN‑38 levels.